Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $23.13 and traded as high as $23.92. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.43, with a volume of 787,068 shares.
Wall Street Analyst Weigh In
A number of research firms have recently commented on FMS. BNP Paribas Exane cut Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 target price on the stock. in a research note on Tuesday, July 28th. Morgan Stanley reissued an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Sanford C. Bernstein lifted their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th. Finally, Citigroup reissued a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Six research analysts have rated the stock with a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has a consensus rating of "Reduce" and a consensus target price of $23.57.
View Our Latest Analysis on Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA Stock Performance
The firm has a market cap of $12.58 billion, a P/E ratio of 12.14, a P/E/G ratio of 4.42 and a beta of 0.77. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The business's 50-day simple moving average is $23.96 and its 200 day simple moving average is $23.13.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The firm had revenue of $5.55 billion for the quarter, compared to analysts' expectations of $5.48 billion. As a group, equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. CIBC Private Wealth Group LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company's stock valued at $36,000 after purchasing an additional 1,103 shares during the last quarter. Arax Advisory Partners grew its position in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company's stock valued at $38,000 after buying an additional 885 shares during the period. Kestra Advisory Services LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $58,000. Finally, Group One Trading LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter worth $74,000. 8.37% of the stock is owned by hedge funds and other institutional investors.
About Fresenius Medical Care AG & Co. KGaA
(
Get Free Report)
Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.
In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Fresenius Medical Care AG & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care AG & Co. KGaA wasn't on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
